Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | INSM |
---|---|---|
09:32 ET | 18884 | 28.045 |
09:34 ET | 22812 | 28.035 |
09:36 ET | 29568 | 27.725 |
09:38 ET | 16363 | 27.8 |
09:39 ET | 13158 | 28.32 |
09:41 ET | 12047 | 28.22 |
09:43 ET | 6400 | 28.33 |
09:45 ET | 18557 | 28.49 |
09:48 ET | 19799 | 28.57 |
09:50 ET | 27396 | 28.64 |
09:52 ET | 58295 | 28.575 |
09:54 ET | 12734 | 28.13 |
09:56 ET | 2746 | 28.09 |
09:57 ET | 9938 | 28.22 |
09:59 ET | 15434 | 28.3 |
10:01 ET | 66967 | 28.46 |
10:03 ET | 19914 | 28.52 |
10:06 ET | 12311 | 28.43 |
10:08 ET | 130881 | 28.375 |
10:10 ET | 37385 | 28.33 |
10:12 ET | 7864 | 28.065 |
10:14 ET | 16909 | 28.175 |
10:15 ET | 109916 | 28.02 |
10:17 ET | 11649 | 27.84 |
10:19 ET | 17485 | 27.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Insmed Inc | 3.3B | -7.9x | --- |
Genmab A/S | 23.1B | 71.3x | --- |
Amicus Therapeutics Inc | 3.4B | -12.6x | --- |
Fate Therapeutics Inc | 3.2B | -13.6x | --- |
Twist Bioscience Corp | 3.0B | -15.1x | --- |
Vitaspring Biomedical Co. Ltd | 3.4B | 2,492.4x | --- |
Insmed Incorporated is a biopharmaceutical company engaged in providing ARIKAYCE (amikacin liposome inhalation suspension) product, which is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which is developing for the treatment of patients with bronchiectasis, cystic fibrosis (CF) and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRS) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3B |
---|---|
Revenue (TTM) | $221.2M |
Shares Outstanding | 119.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.88 |
EPS | $-3.51 |
Book Value | $3.46 |
P/E Ratio | -7.9x |
Price/Sales (TTM) | 15.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -172.16% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.